David Breckenridge

David Breckenridge currently serves as Chief Scientific Officer and Chief Business Officer at Actio Biosciences, Inc. since November 2021. Prior to this role, David was with Gilead Sciences from July 2008, where several positions were held, culminating in Vice President of Research External Innovation. Key contributions include leading research efforts in fibrosis and serving as project lead for BET inhibitor Alobresib and ASK1 inhibitor Selonsertib. David's academic background includes a PhD in Biochemistry from McGill University and a Bachelor of Science in Biochemistry from Dalhousie University, as well as completing a postdoctoral fellowship at the University of Colorado at Boulder.